{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:46:40Z","timestamp":1783644400286,"version":"3.55.0"},"reference-count":30,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4,1]]},"DOI":"10.1210\/jc.2008-2324","type":"journal-article","created":{"date-parts":[[2009,1,27]],"date-time":"2009-01-27T22:59:22Z","timestamp":1233097162000},"page":"1131-1136","source":"Crossref","is-referenced-by-count":62,"title":["Decreased Bone Turnover Despite Persistent Secondary Hyperparathyroidism during Prolonged Treatment with Imatinib"],"prefix":"10.1210","volume":"94","author":[{"given":"Susannah","family":"O'Sullivan","sequence":"first","affiliation":[{"name":"Departments of Medicine (S.O., A.H., D.W., K.C., G.G., A.G.), The University of Auckland, Auckland 1142, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Horne","sequence":"additional","affiliation":[{"name":"Departments of Medicine (S.O., A.H., D.W., K.C., G.G., A.G.), The University of Auckland, Auckland 1142, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Wattie","sequence":"additional","affiliation":[{"name":"Departments of Medicine (S.O., A.H., D.W., K.C., G.G., A.G.), The University of Auckland, Auckland 1142, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran","family":"Porteous","sequence":"additional","affiliation":[{"name":"Molecular Medicine and Pathology (F.P., P.B.), The University of Auckland, Auckland 1142, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Callon","sequence":"additional","affiliation":[{"name":"Departments of Medicine (S.O., A.H., D.W., K.C., G.G., A.G.), The University of Auckland, Auckland 1142, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Gamble","sequence":"additional","affiliation":[{"name":"Departments of Medicine (S.O., A.H., D.W., K.C., G.G., A.G.), The University of Auckland, Auckland 1142, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ebeling","sequence":"additional","affiliation":[{"name":"Department of Medicine (P.E.), Western Hospital, The University of Melbourne, Parkville, Victoria 3050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Browett","sequence":"additional","affiliation":[{"name":"Molecular Medicine and Pathology (F.P., P.B.), The University of Auckland, Auckland 1142, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Grey","sequence":"additional","affiliation":[{"name":"Departments of Medicine (S.O., A.H., D.W., K.C., G.G., A.G.), The University of Auckland, Auckland 1142, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113484559400_R1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate\u2014a new oral targeted therapy.","volume":"346","author":"Savage","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113484559400_R2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113484559400_R3","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/S0959-8049(02)00836-5","article-title":"Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.","volume":"39","author":"Verweij","year":"2003","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t2019041113484559400_R4","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113484559400_R5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1082095","article-title":"LRP: role in vascular wall integrity and protection from atherosclerosis.","volume":"300","author":"Boucher","year":"2003","journal-title":"Science"},{"key":"key\n\t\t\t\t2019041113484559400_R6","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/01.ATV.0000124105.39900.db","article-title":"Imatinib attenuates diabetes-associated atherosclerosis.","volume":"24","author":"Lassila","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t2019041113484559400_R7","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1056\/NEJMc052500","article-title":"Imatinib and hyperlipidemia.","volume":"353","author":"Gottardi","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113484559400_R8","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJM200503103521023","article-title":"Imatinib and regression of type 2 diabetes.","volume":"352","author":"Veneri","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113484559400_R9","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1172\/JCI28546.","article-title":"Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.","volume":"116","author":"Paniagua","year":"2006","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019041113484559400_R10","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-\u03b2 and prevents bleomycin-mediated lung fibrosis.","volume":"114","author":"Daniels","year":"2004","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019041113484559400_R11","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/cncr.11812","article-title":"Imatinib mesylate causes hypopigmentation in the skin.","volume":"98","author":"Tsao","year":"2003","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019041113484559400_R12","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/S0140-6736(03)13554-4","article-title":"Gynaecomastia in men with chronic myeloid leukaemia after imatinib.","volume":"361","author":"Gambacorti-Passerini","year":"2003","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041113484559400_R13","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2019041113484559400_R14","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1056\/NEJMc062388","article-title":"Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism.","volume":"355","author":"Grey","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113484559400_R15","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate.","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113484559400_R16","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients.","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041113484559400_R17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ajh.20778","article-title":"Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.","volume":"82","author":"Osorio","year":"2007","journal-title":"Am J Hematol"},{"key":"key\n\t\t\t\t2019041113484559400_R18","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.","volume":"22","author":"O'Sullivan","year":"2007","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113484559400_R19","first-page":"45","article-title":"General metabolic screening tests","author":"Shih","year":"1991","journal-title":"In: Hommes FA, ed. Techniques in diagnostic human biochemical genetics: a laboratory manual. New York: Wiley-Liss;"},{"key":"key\n\t\t\t\t2019041113484559400_R20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0009-8981(77)90059-6","article-title":"A simple slide-rule method for the assessment of renal tubular reabsorption of phosphate in man.","volume":"81","author":"Walton","year":"1977","journal-title":"Clin Chim Acta"},{"key":"key\n\t\t\t\t2019041113484559400_R21","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2006-2646","article-title":"The peroxisome proliferator-activated receptor-\u03b3 agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial.","volume":"92","author":"Grey","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113484559400_R22","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1001\/archinte.168.20.2276","article-title":"Randomized controlled trial of calcium supplementation in healthy, nonosteoporotic, older men.","volume":"168","author":"Reid","year":"2008","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019041113484559400_R23","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":"Imatinib as a potential antiresorptive therapy for bone disease.","volume":"107","author":"Dewar","year":"2006","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041113484559400_R24","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s10495-006-9507-z","article-title":"Ability of breast cancer cell lines to stimulate bone resorbing activity of mature osteoclasts correlates with an anti-apoptotic effect mediated by macrophage colony stimulating factor.","volume":"11","author":"Gallet","year":"2006","journal-title":"Apoptosis"},{"key":"key\n\t\t\t\t2019041113484559400_R25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2006.09.007","article-title":"Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.","volume":"551","author":"El Hajj Dib","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"key\n\t\t\t\t2019041113484559400_R26","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113484559400_R27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00198-007-0492-z","article-title":"Relationships between fat and bone.","volume":"19","author":"Reid","year":"2008","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113484559400_R28","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.bone.2004.08.009","article-title":"Renal phosphate loss in hereditary and acquired disorders of bone mineralization.","volume":"35","author":"Bielesz","year":"2004","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041113484559400_R29","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1053\/j.ajkd.2007.10.039","article-title":"Partial Fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.","volume":"51","author":"Francois","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019041113484559400_R30","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.bone.2006.12.062","article-title":"FGF23 is a hormone-regulating phosphate metabolism\u2014unique biological characteristics of FGF23.","volume":"40","author":"Fukumoto","year":"2007","journal-title":"Bone"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/4\/1131\/10806566\/jcem1131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T11:27:08Z","timestamp":1558092428000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/94\/4\/1131\/2596234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,1]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2008-2324","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,1]]}}}